BRPI9912663A - vacina contra câncer e polipeptídeo. - Google Patents

vacina contra câncer e polipeptídeo.

Info

Publication number
BRPI9912663A
BRPI9912663A BRPI9912663A BRPI9912663A BRPI9912663A BR PI9912663 A BRPI9912663 A BR PI9912663A BR PI9912663 A BRPI9912663 A BR PI9912663A BR PI9912663 A BRPI9912663 A BR PI9912663A BR PI9912663 A BRPI9912663 A BR PI9912663A
Authority
BR
Brazil
Prior art keywords
polypeptide
cancer vaccine
antigen
amino acid
tumor
Prior art date
Application number
BRPI9912663A
Other languages
English (en)
Inventor
Haruo Sugiyama
Yoshihiro Oka
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16714530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9912663(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of BRPI9912663A publication Critical patent/BRPI9912663A/pt
Publication of BRPI9912663B1 publication Critical patent/BRPI9912663B1/pt
Publication of BRPI9912663B8 publication Critical patent/BRPI9912663B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

patente de invenção: <b>"antígeno de tumor com base nos produtos do gene wt1 supressor de tumor"<d>. um antígeno de tumor que compreende, como um ingrediente ativo, um produto do gene wt1 supressor de tumor de wilms ou um peptídeo composto de 7 a 30 aminoácidos contíguos contendo um aminoácido âncora para ligação ao principal complexo de histocompatibilidade (mhc) de classe i na referida seqüência de aminoácido, e uma vacina compreendendo o referido antígeno.
BRPI9912663-0 1998-07-31 1999-07-30 vacina contra cáncer e polipeptìdeo. BRPI9912663B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21809398 1998-07-31
PCT/JP1999/004130 WO2000006602A1 (fr) 1998-07-31 1999-07-30 Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1

Publications (3)

Publication Number Publication Date
BRPI9912663A true BRPI9912663A (pt) 2001-05-02
BRPI9912663B1 BRPI9912663B1 (pt) 2011-05-31
BRPI9912663B8 BRPI9912663B8 (pt) 2021-07-06

Family

ID=16714530

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9912663-0 BRPI9912663B8 (pt) 1998-07-31 1999-07-30 vacina contra cáncer e polipeptìdeo.

Country Status (15)

Country Link
US (7) US7030212B1 (pt)
EP (3) EP2048160B1 (pt)
JP (2) JP4422903B2 (pt)
KR (1) KR100767554B1 (pt)
CN (4) CN1560078B (pt)
AT (1) ATE420112T1 (pt)
AU (1) AU4932199A (pt)
BR (1) BRPI9912663B8 (pt)
CA (1) CA2337743C (pt)
DE (1) DE69940264D1 (pt)
DK (1) DK1103564T3 (pt)
ES (1) ES2318898T3 (pt)
HK (1) HK1038929B (pt)
PT (1) PT1103564E (pt)
WO (1) WO2000006602A1 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
BRPI9912663B8 (pt) * 1998-07-31 2021-07-06 Int Inst Cancer Immunology Inc vacina contra cáncer e polipeptìdeo.
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
JP4243792B2 (ja) * 1998-09-30 2009-03-25 コリクサ コーポレイション Ｗｔ１特異的免疫療法のための組成物および方法
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
EP1261711A2 (en) * 2000-02-22 2002-12-04 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
EP1371664B1 (en) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
US20060165708A1 (en) * 2001-06-29 2006-07-27 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003028757A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JPWO2003028758A1 (ja) * 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
ATE466084T1 (de) 2002-06-12 2010-05-15 Int Inst Cancer Immunology Inc Hla-a24-restringiertes krebsantigenpeptid
US7342092B2 (en) 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
ATE442378T1 (de) 2002-09-20 2009-09-15 Int Inst Cancer Immunology Inc Substituierte wt1-peptide
JP4498274B2 (ja) 2003-01-15 2010-07-07 株式会社癌免疫研究所 二量体化ペプチド
EP1640458B1 (en) 2003-06-27 2011-12-28 International Institute of Cancer Immunology, Inc. Method of selecting patients suitable for wt1 vaccine
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
SI1731605T1 (sl) * 2004-03-31 2010-07-30 Internat Inst Of Cancer Immunolog Inc Peptidi antigena karcinoma izvedeni iz WT1
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
SI1961761T1 (sl) * 2005-11-30 2010-12-31 Int Inst Cancer Immunology Inc Nove peptidne spojine iz Wilmsovega tumorja
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
GB2440528A (en) * 2006-07-27 2008-02-06 Ist Superiore Sanita Antigen-antibody complexes
JP5239041B2 (ja) 2007-02-07 2013-07-17 一般財団法人阪大微生物病研究会 癌の治療剤
CA2677075C (en) 2007-02-27 2018-07-10 International Institute Of Cancer Immunology, Inc. Method for activation of helper t cell and composition for use in the method
MX2009009589A (es) 2007-03-05 2009-09-21 Int Inst Cancer Immunology Inc Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos.
EP2228072B1 (en) * 2007-12-05 2018-06-13 International Institute of Cancer Immunology, Inc. Cancer vaccine composition
NZ609460A (en) 2010-10-05 2015-07-31 Otsuka Pharma Co Ltd Method for activating helper t cell
CN107238706A (zh) 2011-06-28 2017-10-10 株式会社癌免疫研究所 肽癌抗原‑特异性t细胞的受体基因
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
AU2012335073B2 (en) 2011-11-11 2017-08-17 Fred Hutchinson Cancer Center Cyclin A1-targeted T-cell immunotherapy for cancer
EP2792745B1 (en) 2011-12-14 2017-11-15 National University Corporation Kochi University Modification of helper t cell-inducing polypeptide
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
US20150150975A1 (en) * 2012-07-02 2015-06-04 Sumitomo Dainippon Pharma Co., Ltd. Transdermal cancer antigen peptide preparation
CA2892660C (en) 2012-12-17 2022-02-15 Otsuka Pharmaceutical Co., Ltd. Method for activating helper t cell
EP3769782A1 (en) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
KR102045029B1 (ko) 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
CN103961305B (zh) * 2013-02-05 2019-10-18 日东电工株式会社 经皮给予用wt1肽癌症疫苗带状制剂
KR20140100417A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 백신 조성물
EP2762157A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
RU2014102945A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция
CA2840974A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for mucosal administration
JP6512567B2 (ja) * 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
US9663563B2 (en) * 2013-03-12 2017-05-30 Sumitomo Dainippon Pharma Co., Ltd. Aqueous liquid composition
EP2980097A4 (en) 2013-03-29 2017-03-08 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of erap1
EP3461493A1 (en) * 2013-03-29 2019-04-03 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
JP6712261B2 (ja) 2014-08-04 2020-06-24 フレッド ハッチンソン キャンサー リサーチ センター Ｗｔ−１に特異的なｔ細胞免疫治療
JP6580581B2 (ja) 2014-09-27 2019-09-25 大日本住友製薬株式会社 注射用医薬組成物
TWI759270B (zh) * 2015-09-10 2022-04-01 美國紀念斯隆 凱特琳癌症中心 藉由t細胞療法治療多發性骨髓瘤及漿細胞白血病之方法
EP3377516B1 (en) 2015-11-20 2022-06-15 Memorial Sloan Kettering Cancer Center Composition for treating cancer
CN109069599A (zh) * 2016-03-03 2018-12-21 法国古士塔柏罗斯学院 针对癌症的基于ptp的疫苗
JP7209963B2 (ja) 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
WO2018181648A1 (ja) 2017-03-30 2018-10-04 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
US12570712B2 (en) 2018-02-12 2026-03-10 Fred Hutchinson Cancer Center Cyclin A1 specific T cell receptors and uses thereof
KR20210068060A (ko) 2018-09-28 2021-06-08 다이니뽄 스미토모 세이야쿠 가부시키가이샤 주사용 조성물
EP3865146A4 (en) * 2018-10-05 2022-06-29 International Institute of Cancer Immunology, Inc. Prophylactic or therapeutic drug for benign tumor
TWI875736B (zh) 2019-02-28 2025-03-11 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
AU2020237043A1 (en) 2019-03-11 2021-09-30 Fred Hutchinson Cancer Center High avidity WT1 T cell receptors and uses thereof
US20220409661A1 (en) 2019-08-20 2022-12-29 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for wt-1
IL294290A (en) 2019-12-31 2022-08-01 Elixirgen Therapeutics Inc Transient temperature-based delivery of nucleic acids and proteins to cells and tissues
CN115867303A (zh) 2020-05-12 2023-03-28 住友制药株式会社 用于治疗癌症的药物组合物
EP4149534A4 (en) * 2020-05-12 2024-09-04 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
EP4385519A4 (en) 2021-08-12 2025-08-06 Int Inst Cancer Immunology Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING OR PREVENTING CANCER

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122018A (ja) 1984-07-06 1986-01-30 Green Cross Corp:The 癌免疫療法増強剤
JP2546254B2 (ja) 1987-02-23 1996-10-23 澁谷工業株式会社 ガス詰め充填装置
US5726288A (en) * 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
EP0453560B1 (en) 1989-11-13 1999-05-26 Massachusetts Institute Of Technology Localization and characterization of the wilms' tumor gene
US5731160A (en) 1992-05-26 1998-03-24 Rijksuniversiteit Leiden Induction of antigen specific T-lymphocyte responses by stimulation with peptide loaded MHC class I molecules on antigen processing defective mammalian cell lines
JPH09506866A (ja) 1993-12-14 1997-07-08 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 医薬として活性のある物質の免疫療法のための放出制御
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
PT772619E (pt) 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
ATE332710T1 (de) 1995-06-01 2006-08-15 Kishimoto Tadamitsu Wachstumsinhibitor gegen leukämische zellen, der antisense-oligonukleotidderivate gegen das wilms- tumorgen enthält
JP3904260B2 (ja) * 1995-06-01 2007-04-11 岸本 忠三 ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
EP1728441A3 (de) 1995-09-19 2007-03-07 Bayer BioScience GmbH Pflanzen, die eine modifizierte Stärke synthetisieren, Verfahren zu ihrer Herstellung sowie modifizierte Stärke
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
JPH09191635A (ja) 1996-01-05 1997-07-22 Toshio Aida モータ
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
JP4789095B2 (ja) 1997-07-16 2011-10-05 治夫 杉山 ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
US20030092656A1 (en) 1997-07-16 2003-05-15 Haruo Sugiyama Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
US5985264A (en) 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
BRPI9912663B8 (pt) * 1998-07-31 2021-07-06 Int Inst Cancer Immunology Inc vacina contra cáncer e polipeptìdeo.
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030215458A1 (en) 1998-09-30 2003-11-20 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
JP4243792B2 (ja) 1998-09-30 2009-03-25 コリクサ コーポレイション Ｗｔ１特異的免疫療法のための組成物および方法
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU760574B2 (en) 1999-01-12 2003-05-15 Smithkline Beecham Biologicals (Sa) Novel treatment
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
JP2001089389A (ja) 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd 抗原特異的ｔ細胞の誘導剤
DE60026666T2 (de) 1999-07-22 2006-11-09 Dainippon Sumitomo Pharma Co., Ltd. Induktion von antigen-spezifischen T-Zellen durch Interferon
EP1261711A2 (en) 2000-02-22 2002-12-04 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
EP1371664B1 (en) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003028757A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JPWO2003028758A1 (ja) 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
ATE466084T1 (de) 2002-06-12 2010-05-15 Int Inst Cancer Immunology Inc Hla-a24-restringiertes krebsantigenpeptid
US7342092B2 (en) 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
ATE442378T1 (de) 2002-09-20 2009-09-15 Int Inst Cancer Immunology Inc Substituierte wt1-peptide
JP4498274B2 (ja) 2003-01-15 2010-07-07 株式会社癌免疫研究所 二量体化ペプチド
EP1640458B1 (en) 2003-06-27 2011-12-28 International Institute of Cancer Immunology, Inc. Method of selecting patients suitable for wt1 vaccine
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
SI1731605T1 (sl) 2004-03-31 2010-07-30 Internat Inst Of Cancer Immunolog Inc Peptidi antigena karcinoma izvedeni iz WT1

Also Published As

Publication number Publication date
HK1038929B (zh) 2005-05-06
DE69940264D1 (de) 2009-02-26
WO2000006602A1 (fr) 2000-02-10
US20090143291A1 (en) 2009-06-04
EP2280031B1 (en) 2015-04-15
HK1036073A1 (en) 2001-12-21
DK1103564T3 (da) 2009-05-11
US7608685B1 (en) 2009-10-27
CN100560130C (zh) 2009-11-18
EP2280031A1 (en) 2011-02-02
CN1178956C (zh) 2004-12-08
US20160243209A1 (en) 2016-08-25
CN1560078B (zh) 2011-06-22
EP1103564A4 (en) 2005-02-02
US7517950B2 (en) 2009-04-14
PT1103564E (pt) 2009-03-13
US20050266014A1 (en) 2005-12-01
CN1560078A (zh) 2005-01-05
EP1103564B1 (en) 2009-01-07
JP4422903B2 (ja) 2010-03-03
KR20010072112A (ko) 2001-07-31
HK1130069A1 (en) 2009-12-18
ATE420112T1 (de) 2009-01-15
US7807792B2 (en) 2010-10-05
CN102198266A (zh) 2011-09-28
HK1038929A1 (en) 2002-04-04
JP2010059172A (ja) 2010-03-18
CN1762490A (zh) 2006-04-26
JP5230579B2 (ja) 2013-07-10
CA2337743A1 (en) 2000-02-10
BRPI9912663B1 (pt) 2011-05-31
US20060093615A1 (en) 2006-05-04
KR100767554B1 (ko) 2007-10-17
US7390871B2 (en) 2008-06-24
US20090281043A1 (en) 2009-11-12
AU4932199A (en) 2000-02-21
US9403886B2 (en) 2016-08-02
EP2048160A1 (en) 2009-04-15
BRPI9912663B8 (pt) 2021-07-06
ES2318898T3 (es) 2009-05-01
EP2048160B1 (en) 2015-01-07
CA2337743C (en) 2015-07-07
EP1103564A1 (en) 2001-05-30
CN1314916A (zh) 2001-09-26
HK1153761A1 (en) 2012-04-05
US7030212B1 (en) 2006-04-18

Similar Documents

Publication Publication Date Title
BRPI9912663A (pt) vacina contra câncer e polipeptídeo.
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
BR9607383A (pt) Composição farmacêutica útil para a transfecção de um ácido nucléico e utilização desta composição
ATE262348T1 (de) Mittel zur verabreichung von antigenen
BRPI0208183B8 (pt) peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
NO962791D0 (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
EP3263585A3 (en) Foxm1 peptide and medicinal agent comprising the same
BR9812634A (pt) April - uma proteìna com efeitos de crescimento
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
BR9814204A (pt) &#34;obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral&#34;
NO965621D0 (no) Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4
NZ309659A (en) Composition comprising LbeIF4A and/or LmeIF4A polypeptides (Leishmania antigen) and methods for enhancing immune responses
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
NL300830I1 (nl) Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten
AU4263696A (en) Peptides capable of binding to the gap protein sh3 domain, nucleotide sequences coding therefor, and preparation and use thereof
AUPN154295A0 (en) Nucleic acid molecule encoding a protein with avian gamma-interferon activity
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
BRPI0209416A2 (pt) Novos vetores de expressão e uso dos mesmos
TR200003498T2 (tr) Amino asit sekansından oluşan bir polipetit, bunun aşıları ve kullanımları
BR9814958A (pt) Proteìna de cimento de tecido, composição farmacêutica, uso da proteìna de cimento de tecido, vacina, processos para produção de vacina, para ligação de tecido de animal e para preparação de uma protéina de cimento de tecido, molécula de ácido nucleico, vetor de expressão ou de clonagem, célula hospedeira, e, animal transgênico
BR9811954A (pt) ácidos 3-aril-succinamido-hidroxâmicos, processos para sua produção e preparações farmacêuticas contendo estas substâncias
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht